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The most extensive exchange of letters in the history of Brain (Gelfand et al. 2012). was about a 
minuscule region of the eye, the retinal inner nuclear layer (INL). With the advent of optical 
coherence tomography (OCT), a forgotten autopsy observation was restored to the top of the 
current research agenda in multiple sclerosis (MS) (Gelfand et al. 2012). Severe atrophy of the 
retinal nerve fibre layer (RNFL) and ganglion cell layer (GCL) was associated with subtle changes in 
the INL whilst the outer retinal layers were completely preserved (Müller 1857). Whilst very 
cautious about potential INL changes1, Heinrich Müller was howevermore convinced about the 
existence of secondary (retrograde) axonal degeneration. Histological analysis of the macaque 
monkey eye following lesions to the chiasm and occipital cortex provided experimental evidence 
for retrograde trans-synaptic degeneration reaching the GCL with associated changes in the INL 
(van Buren 1963). Lesions of the optic chiasm led to thinning of the RNFL and GCL with the 
formation of cystic spaces in the INL which “were irregularly rounded and the larger contained fine 
strands of tissue and debris”. Occipital cortex lesions, by contrast, did not affect the INL or any of 
the outer retinal layers. These INL changes are the likely histological equivalent of what has been 
called “microcystic macular oedema” (MMO) (Gelfand et al. 2012). I will later return to the debate 
surrounding MMO in an attempt to explain the next relevant observation, the increase in INL 
thickness in the absence of obvious MMO. Increased thickening of the pooled outer plexiform and 
inner nuclear layers was found to be associated with signs of inflammation in MS (Saidha et al. 
2012). Together these studies raised the possibility that MMO and INL thickening might be 
comparable to an MRI “T2 lesion” and could be useful as a surrogate outcome for treatment trials 
in MS (Petzold 2012). In this issue of Brain, Knier et al. report that disease-modifying treatment in 
patients with MS efficiently controlled inflammatory disease activity and was associated with INL 
volume reduction (Knier et al., 2016). 
 
Recruitment for the present study started right at the time of publication of the two landmark INL 
papers by Gelfand and Saidha (Saidha et al. 2012). Three years later 121 patients suffering from 
relapsing-remitting MS and 40 healthy control subjects had been enrolled. Patients were grouped 
into those who had received no disease-modifying therapy (no DMT, n=36), a first line drug (1st 
DMT, n=47) or a second line drug (2nd DMT, n=25). Not surprisingly the latter subgroup consisted 
of patients who had significantly more disease activity based on clinical and radiological criteria. 
   
A frequent criticism of OCT studies is the potential bias caused by inclusion of MSON.About 
80%eople of patients with MS will at some time experience an episode of MS-associated optic 
                                                     
1 “Die sogenannten Körner erschienen etwas körnig, doch war mir sehr zweifelhaft, ob dies als pathologische 
Veränderung anzusprechen sei, da man Aehnliches auch sonst zu Gesicht bekommt.” This case was discussed on 
pages 92-98 and the citation taken from page 93 (Müller 1857). For the contemporary translation it is important to 
refer back to the terminology of the time. There were three “Körnerschichten“ which correspond to the present 
day “Ganglion cell layer”, “Inner nuclear layer” and “Outer nuclear layer”. Müller was not able to see the 
Ganglion cell layer and his comment is on the next nuclear layer, the inner nuclear layer: “The so called nuclei seemed 
more grainy, but I am rather doubtful if this should be interpreted as a (specific) pathological finding as one can see 
similar features in other situations.” 
neuritis (MSON). These patients have more severe damage to the inner retinal layers and more 
frequently MMO. A frequent criticism of OCT studies is the potential bias caused by inclusion of 
MSON. In fact, in the present study MMO was only observed in patients with MSON. In total MMO 
was present in 3/121185 eyespatients (1.6%), which is comparable to previously reported values 
of 1% (Balk et al. 2012), 4.7% (Gelfand et al. 2012) and 6% (Saidha et al. 2012). Knier et al. are 
therefore to be commended for having excluded patients with MSON prior to enrolment or during 
the study period before moving on to the exciting statistical analysis of INL volume changes.  
 
Consistent with the literature, there was more severe atrophy in the inner retinal layer in patients 
with MS compared to controls (see Table 1 in Knier et al). In patients, a larger INL volume was 
predictive of a greater number of new contrast-enhancing and T2 MRI lesions (see Figure 1 in 
Knier et al). Whilst both observations must come as a reassurance, the truly novel finding is shown 
in the next figure. Even those unfamiliar with OCT will immediately spot that the standardised 
effect size for one retinal layer stands out, the INL (Figure 2A in Knier et al.). Volume reduction of 
the INL was related to clinical and radiological evidence of reduced inflammatory disease activity. 
A potential bias owing to the presence of new optic tract T2 lesions was carefully excluded (Figure 
2B in Knier et al). Even a critical examination of the corresponding tables reveals odds ratios with 
narrow confidence intervals and highly significant findings for the INL. 
 
Having prepared the ground, the authors present the effect of treatment on individual retinal 
layers. Particularly striking is the trend shown by the relative changes in three-monthly 
longitudinal OCT data (Figure 3D in Knier et al.). In patients in whom inflammatory disease activity 
completely ceases, one observes a reduction of the INL volume within 6 months. This trend 
continues for the entire observation period up to 18 months. In contrast, no changes of the INL 
volume were observed in those patients in whom inflammatory disease activity could not be 
controlled. So is INL volume reduction a response marker for successful treatment of inflammation 
in MS? 
 
At the beginning of this commentary, I wrote that the discovery of MMO and volume changes of 
the INL triggered possibly the most extensive exchange of letters on a single subject in the history 
of Brain (full list of references available from author). It seems about time to review the key points 
covered in this heated debate. Credit is due to Matthias Abegg for having pointed out that MMO 
may be caused by retrograde axonal degeneration as a result of any type of lesion in the anterior 
optic pathways (Abegg et al 2012). He continued to pursue this subject, proposing the term 
“retrograde maculopathy”. At the same time my own group showed that MMO was not specific to 
MS, and suggested that an impaired capacity of Müller cells to maintain retinal fluid homoeostasis 
might be relevant (Balk et al. 2012). The Müller cell hypothesis enabled Abegg to show that INL 
volume can be reduced by treatment of MMO with acetazolamide, which improves the water-
pumping function of Müller cells (Abegg 2016). But it has also been suggested that MMO results 
from neither inflammatory nor trans-synaptic degeneration (Barboni et al 2013). Might traction at 
the vitreoretinal interface also be involved (Petzold 2012, Lujan and Horton 2013)? And why was 
MMO transient in 84% of cases (Burggraaff et al. 2014)? 
 
In summary, the Knier et al. study takes the discovery of MMO and INL volume changes (Gelfand 
et al. 2012, Saidha et al. 2012) to the next level. But because it is essentially correlative, it further 
emphasises the need for a comprehensive understanding of the underlying mechanisms in the 
retina. Taken together the observations imply that dynamic fluid shifts, likely related to 
inflammation, vascular permeability and Müller cell function need to be considered, as well as 
non-inflammation related changes such as traction and a retrograde maculopathy. The location of 
MMO suggests a close relationship to the retinal vasculature (Balk et al. 2012). Müller cell Müller 
cellprocesses encompass the capillary plexus of the retina (Figure). Above the INL lies the 
superficial vascular plexus; below the INL lies the deep capillary plexus. Both are readily visualised 
by OCT angiography and are connected vertically by small vessels. Understanding fluid trafficking 
through the retina will now be important to better explain volume changes of the INL: the Figure 
accompanying this commentary summarises the potential mechanisms involved.  
 
cancausing tissue expansion  
 
 
To conclude, patient numbers in the exciting longitudinal data presented by Knier et al. (Figure 3D) 
were small, but this throws down the gauntlet to everyone who can get their hands on existing MS 
OCT trial data. Can reduction of INL volume be validated as a biomarker for sustained control of 
autoimmune central nervous system inflammation by therapeutic interventions? Publication of 














Optical Coherence Tomography (OCT): A non-invasive, very fast method which permits 
construction of an image based on the amount of light reflected (back scattered) from tissue. The 
axial resolution of current spectral domain OCT devices is 3–7 µm. For comparison the thickness of 
a retinal ganglion cell is 5–20 µm. OCT therefore permits in vivo research on a cellular level. 
 
Trans-synaptic axonal degeneration: A key concept underlying OCT research in MS. Trans-synaptic 
axonal degeneration explains why it is possible to measure atrophy of inner retinal layers with OCT 
in patients with MS, with or without MSON. Any lesion in a hard wired pathway, such as the 
projection from the retinal ganglion cell to the primary visual cortex will result in axonal 
degeneration. The direction of axonal degeneration is described as anterograde (or Wallerian) if it 
moves away from its neuron and retrograde if it moves towards its neuron. A key question which 
remains to be answered is why degeneration moves on to the next, supposedly “healthy” neuron. 
In a “domino effect” all neurons in the hard wired visual pathway eventually succumb to 
neurodegeneration, including 1st order neurons in the retinal ganglion cell layer 2nd order neurons 
in the dorsal lateral geniculate nucleus and 3rd order neurons in the primary visual cortex. In the 
strict definition of this single pathway model, absent excitatory input from presynaptic cells might 
be an attractive hypothesis. Alternatively one might think of “nexopathies” and transport of 
“toxic”/damaged proteins or aggregates. From a therapeutic point of view targeting trans-synaptic 
axonal degeneration will likely be more promising then trying to cure axonotmesis. 
 
.The brain glymphatic system this   
  
Figure. Schematic illustration of a retinal glymphatic system which can account for the OCT 
observations made on MMO and INL volume changes.  
(A) The Müller cells are shown in green. Water and potassium channels (black dotted lines) 
are expressed where the foot plates which form the inner limiting membrane (top 
horizontal black line) are in contact with the retinal blood vessels. The bipolar cells of the 
INL (grey box) are shown in purple, cones in red and rods in pink. Horizontal (dark blue) 
and amacrine (light blue) cells contribute to the neuronal network of the INL. The retinal 
ganglion cell (yellow) extends its axon into what can be seen as the retinal nerve fibre layer 
(RNFL) by optical coherence tomography (OCT). Channels for potassium (Kir4.1 and Kir2.1) 
and water (aquaporin 4) are also scattered, albeit at a much lower density, over the entire 
Müller cell membrane. The superficial vascular and deep capillary plexus (red circles) 
localise to the upper and lower borders of the INL. Fluid reaches the retina through the 
internal limiting membrane and the plexus (blue double arrows). Under normal condition 
both plexus and Müller cells can absorb the interstitial fluid (black double arrows). (B) With 
inflammation, diffusion of fluid from the retinal blood vessels increases. Possibly disruption 
of the blood-retina barrier (BRB) would permit additional extravasation of osmotic agents, 
which would increase the oncotic pressure of fluids in the extracellular space. Activation of 
resting microglia and B-cell migration may contribute further. Together this would make it 
more difficult for Müller cells to maintain retinal fluid homoeostasis. A new equilibrium 
would result with potentially transient tissue expansion. This would be detected by OCT as 
an increase of INL volume (larger grey shared area). (C) The possibility of pathology of 
Müller cells or the retinal vasculature needs to be considered, too. This could impair the 
absorption of interstitial fluid and buffering of osmotic agents. (D) Mechanisms unrelated to 
a retinal glymphatic system may also be involved. (E) The study by Knier et al. placed in 
context. At baseline patients with MS have evidence of inflammatory activity. The retinal 
glymphatic system is impaired and consequently the INL volume is increased. Treatment 
with fingolimod, a strong modulator or Sphingosine-1-phosphate (S1P) receptors, and the 
multilevel anti-inflammatory effect of interferons reduce the systemic inflammatory 
response, including in the retina. Reduction of the inflammatory response enables the 
retinal glymphatic system to recover its function, and consequently the INL volume is 
reduced.  
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